Literature DB >> 18383882

Lymph node metastasis density (ND)-factor association with malignant degree and ND40 as "non-curative factor" in gastric cancer.

Keishi Yamashita1, Akira Ooki, Shinichi Sakuramoto, Shiroh Kikuchi, Natsuya Katada, Nobuyuki Kobayashi, Masahiko Watanabe.   

Abstract

UNLABELLED: Advanced gastric cancer is not controlled by surgery alone, although early gastric cancer can be cured by curative gastrectomy. The TNM factor, representing physical tumor spread, accurately predicts patient prognosis in advanced gastric cancer, however, more elaborate prognostic factors reflecting the malignant degree are necessary in order to determine the therapeutic target. The purpose of this study was to select a significant prognostic indicator of gastric cancer with curative intent, independent of TNM stage among daily-feasible clinical parameters. The current study included 382 patients with stage IB to III gastric cancer after curative surgery, in which the robust univariate prognostic predictors were age (p < 0.0001), lymph node metastasis density of 40% or over (ND40) (p < 0.0001), and preoperative high value of carcinoembryonic antigen (CEA) (preCEA) (p = 0.0012), as well as TNM stage, preoperative high value of CA19-9 (preCA19-9), a glyco-chain antigen recognized by monoclonal antibody NS19-9, and vascular invasion. In multivariate prognostic analysis, age (p = 0.0002), ND40 (p = 0.02), and preCEA (p = 0.03) remained independent prognostic factors. The ND-factor provided excellent prognostic stratification within the same stage, and stage III ND40 predicted a similar prognosis to stage IV and could be considered a non-curative factor. Interestingly, ND40 relevance was validated in the prospective and independent set of gastric cancer patients (p = 0.002).
CONCLUSION: The ND factor reflects the malignant degree of gastric cancer, and ND40 is a novel "non-curative factor" in gastric cancer patients. A search for the molecules associated with higher ND value within an identical stage could lead to objective determination of the degree of malignancy and development of novel strategies against advanced gastric cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18383882

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients.

Authors:  Shinichi Sakuramoto; Keishi Yamashita; Masahiko Watanabe
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

2.  Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery.

Authors:  S Dixit; M Tilston; W M Peter
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

3.  Lectin microarray technology identifies specific lectins related to lymph node metastasis of advanced gastric cancer.

Authors:  Keishi Yamashita; Atsushi Kuno; Atsushi Matsuda; Yuzuru Ikehata; Natsuya Katada; Jun Hirabayashi; Hisashi Narimatsu; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2015-04-04       Impact factor: 7.370

4.  Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy.

Authors:  Akira Ema; Keishi Yamashita; Shinich Sakuramoto; Guoqin Wang; Hiroaki Mieno; Masayuki Nemoto; Tomotaka Shibata; Natsuya Katada; Shiro Kikuchi; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2013-06-26       Impact factor: 7.370

5.  Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.

Authors:  Akira Ooki; Kiwamu Akagi; Toshimasa Yatsuoka; Masako Asayama; Hiroki Hara; Yoji Nishimura; Hiroshi Katoh; Keishi Yamashita; Masahiko Watanabe; Kensei Yamaguchi
Journal:  J Gastrointest Surg       Date:  2017-03-01       Impact factor: 3.452

6.  The impact of lymph node density on survival of cervical cancer patients.

Authors:  S Polterauer; L Hefler; V Seebacher; J Rahhal; C Tempfer; R Horvat; A Reinthaller; C Grimm
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

7.  Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.

Authors:  Akira Ema; Mina Waraya; Keishi Yamashita; Kenichi Kokubo; Hirosuke Kobayashi; Keika Hoshi; Yoshiko Shinkai; Hiroshi Kawamata; Kazunori Nakamura; Hiroshi Nishimiya; Natsuya Katada; Masahiko Watanabe
Journal:  Cancer Med       Date:  2014-08-26       Impact factor: 4.452

8.  The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients.

Authors:  Kai Deng; Li Yang; Bing Hu; Hao Wu; Hong Zhu; Chengwei Tang
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

9.  The H19-PEG10/IGF2BP3 axis promotes gastric cancer progression in patients with high lymph node ratios.

Authors:  Satoru Ishii; Keishi Yamashita; Hiroki Harada; Hideki Ushiku; Toshimichi Tanaka; Nobuyuki Nishizawa; Keigo Yokoi; Marie Washio; Akira Ema; Hiroaki Mieno; Hiromitsu Moriya; Kei Hosoda; Mina Waraya; Hiroshi Katoh; Masahiko Watanabe
Journal:  Oncotarget       Date:  2017-08-05

Review 10.  Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis.

Authors:  Yong-xi Song; Xuan-zhang Huang; Peng Gao; Jing-xu Sun; Xiao-wan Chen; Yu-chong Yang; Cong Zhang; Hong-peng Liu; Hong-chi Wang; Zhen-ning Wang
Journal:  Dis Markers       Date:  2015-10-21       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.